Perrigo (NYSE:PRGO) has been given a consensus recommendation of “Hold” by the twenty brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $91.88.
PRGO has been the topic of a number of analyst reports. Canaccord Genuity set a $100.00 price objective on Perrigo and gave the stock a “buy” rating in a research report on Monday, January 1st. Cantor Fitzgerald set a $107.00 price objective on Perrigo and gave the stock a “buy” rating in a research report on Thursday, December 28th. Finally, Berenberg Bank initiated coverage on Perrigo in a research report on Thursday, February 1st. They set a “buy” rating and a $117.00 price objective on the stock.
In other news, CEO Uwe Roehrhoff acquired 7,500 shares of the company’s stock in a transaction dated Monday, March 5th. The stock was acquired at an average cost of $81.85 per share, with a total value of $613,875.00. Following the completion of the purchase, the chief executive officer now owns 4,900 shares of the company’s stock, valued at approximately $401,065. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.
Perrigo stock traded down $0.67 during trading on Wednesday, reaching $81.81. 133,935 shares of the company were exchanged, compared to its average volume of 1,020,454. Perrigo has a 52-week low of $63.68 and a 52-week high of $95.93. The company has a market cap of $11,473.71, a price-to-earnings ratio of 16.62, a PEG ratio of 2.02 and a beta of 0.76. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.96.
Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Thursday, March 1st. The company reported $1.28 EPS for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.03. Perrigo had a return on equity of 11.54% and a net margin of 2.42%. The firm had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter last year, the business posted $1.24 earnings per share. The firm’s revenue was down 3.6% compared to the same quarter last year. analysts predict that Perrigo will post 5.23 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 20th. Stockholders of record on Friday, March 2nd were paid a $0.19 dividend. The ex-dividend date was Thursday, March 1st. This is a boost from Perrigo’s previous quarterly dividend of $0.16. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.93%. Perrigo’s payout ratio is presently 15.42%.
TRADEMARK VIOLATION NOTICE: This story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2018/04/25/perrigo-prgo-given-average-recommendation-of-hold-by-brokerages.html.
Perrigo Company Profile
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.